Abstract 1604P
Background
Analysis of the most common prevalent symptoms among patients with advanced cancer diagnosis is needed in order to reach the most appropriate interventions leading to improved quality of life of these patients. The aim of this study is to report on the overall symptom prevalence among patients with advanced cancer diagnosis under palliative care and to analyze the difference of symptom prevalence between elderly (≥ 65 years) and adult (<65 years) patients.
Methods
A retrospective cohort study of 400 patients with advanced cancer who were admitted under palliative care between 1st January 2017 to December 31st, 2021. Data were retrieved from electronic medical records.
Results
Anorexia (91%), fatigue (98%), drowsiness (84%) and pain (83%) were the highest 4 prevalent symptoms for the whole group, followed by depression (76%) and anxiety (72%). Adult patients had significant higher pain (80% versus 76%), depression (83% versus 68%) and anxiety (77% versus 65%), compared to elderly (≥ 65 years) patients. On multivariate analysis, pain only was significantly higher in adult patients (p=0.021). The reported percentage of symptom prevalence for the whole group is higher than that in the literature, indicating late referral to palliative care.
Conclusions
There is a high percentage of symptom prevalence among our patients and a short median overall survival that indicates late referral to palliative care. Adult patients had significantly higher pain, depression, and anxiety compared to elderly patients. An earlier integration of palliative care is recommended in the overall management of our patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical Research Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2018P - Novel nomogram based on the expression of DLL3 and PD-L1 for predicting the prognosis of small cell lung cancer patients
Presenter: Jun Zhao
Session: Poster session 05
2019P - Analysis of lung immune prognostic index (LIPI) score in a small cell lung cancer carcinoma (SCLC) cohort, supporting its prognostic use and investigating its predictive potential
Presenter: Mónica Esteban García
Session: Poster session 05
2020P - Circulating micro RNAs (cmiRNAs) as treatment outcome predictors in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab plus carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2021P - Cell-free (cf) DNA as predictive biomarker (B) of treatment outcome in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab, carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2022P - ALBA project: Prognostic impact of laterality in small cell lung cancer
Presenter: Lorenza Landi
Session: Poster session 05
2024P - Supportive measures to control myelosuppression and costs for patients with SCLC with lurbinectedin, CAV or topotecan with or without trilaciclib: A review on the basis of clinical trials
Presenter: Manuel Dómine
Session: Poster session 05
2025P - Stratified control study of neuroendocrine differentiation and potential clinicopathologic markers
Presenter: Li Liu
Session: Poster session 05
2026P - Small cell lung cancer (SCLC) in the KBP-2020-CPHG cohort and comparison with 2000 and 2010
Presenter: Lionel Falchero
Session: Poster session 05
2027P - Immune checkpoint inhibitors in the treatment of small cell lung cancer: A systematic review and meta-analysis
Presenter: Patsy Lee
Session: Poster session 05